

Peter L Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11366617/publications.pdf>

Version: 2024-02-01

192
papers

13,847
citations

36303

51
h-index

22832

112
g-index

195
all docs

195
docs citations

195
times ranked

8140
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2010, 363, 2587-2599. | 27.0 | 4,268 |
| 2 | Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829. | 9.1 | 1,039 |
| 3 | Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125. | 12.4 | 807 |
| 4 | Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75. | 5.1 | 535 |
| 5 | Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 384-390. | 1.1 | 257 |
| 6 | Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 239-254. | 13.7 | 245 |
| 7 | Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 182 |
| 8 | Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. <i>Lancet</i> , The, 2022, 399, 1779-1789. | 13.7 | 177 |
| 9 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 240-250. | 3.0 | 159 |
| 10 | Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 32-43. | 1.1 | 148 |
| 11 | Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 441-449. | 2.1 | 146 |
| 12 | Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 298-303. | 2.1 | 143 |
| 13 | Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. <i>Aids</i> , 2002, 16, 551-560. | 2.2 | 133 |
| 14 | Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580. | 5.8 | 132 |
| 15 | Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. <i>Lancet HIV</i> , the, 2018, 5, e136-e145. | 4.7 | 130 |
| 16 | The Cellular Pharmacology of Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. <i>Clinical Infectious Diseases</i> , 2004, 38, 743-753. | 5.8 | 127 |
| 17 | Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736. | 2.5 | 125 |
| 18 | Review and management of drug interactions with boceprevir and telaprevir. <i>Hepatology</i> , 2012, 55, 1620-1628. | 7.3 | 123 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. <i>Aids</i> , 2003, 17, 2159-2168. | 2.2 | 121 |
| 20 | Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. <i>Aids</i> , 2009, 23, 1035-1046. | 2.2 | 121 |
| 21 | Zidovudine triphosphate and lamivudine triphosphate concentrationâ€“response relationships in HIV-infected persons. <i>Aids</i> , 2000, 14, 2137-2144. | 2.2 | 103 |
| 22 | Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors. <i>Clinical Infectious Diseases</i> , 2000, 30, S151-S159. | 5.8 | 103 |
| 23 | Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. <i>Aids</i> , 2017, 31, 1709-1714. | 2.2 | 103 |
| 24 | Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 122, 16-20. | 2.8 | 100 |
| 25 | High preâ€“exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. <i>Journal of the International AIDS Society</i> , 2017, 20, 21472. | 3.0 | 98 |
| 26 | Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LCâ€“MS/MS detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 390-401. | 2.8 | 97 |
| 27 | Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. <i>New England Journal of Medicine</i> , 2017, 376, 501-502. | 27.0 | 97 |
| 28 | Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78. | 4.7 | 96 |
| 29 | Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017. | 5.8 | 96 |
| 30 | PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003670. | 8.4 | 87 |
| 31 | Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. <i>Current HIV/AIDS Reports</i> , 2020, 17, 301-314. | 3.1 | 83 |
| 32 | Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219. | 5.8 | 82 |
| 33 | Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. <i>Clinical Infectious Diseases</i> , 2016, 63, 1661-1667. | 5.8 | 78 |
| 34 | Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 530-537. | 2.1 | 73 |
| 35 | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 13-20. | 2.1 | 72 |
| 36 | Liquid chromatographyâ€“tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 147-156. | 2.3 | 71 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. <i>Lancet HIV</i> , 2017, 4, e522-e528. | 4.7 | 69 |
| 38 | HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227. | 4.0 | 68 |
| 39 | Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 981-991. | 1.1 | 66 |
| 40 | Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018, 286, 315-325. | 9.9 | 66 |
| 41 | Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e104-e106. | 2.1 | 64 |
| 42 | Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537. | 2.1 | 63 |
| 43 | Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 236-242. | 3.2 | 62 |
| 44 | Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406. | 4.0 | 62 |
| 45 | Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, 1335-1342. | 5.8 | 61 |
| 46 | Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 501-511. | 2.1 | 60 |
| 47 | Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697. | 3.2 | 59 |
| 48 | Indinavir plasma protein binding in HIV-1-infected adults. <i>Aids</i> , 2000, 14, 2293-2297. | 2.2 | 56 |
| 49 | Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 317-325. | 5.8 | 54 |
| 50 | Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 60, 804-810. | 5.8 | 53 |
| 51 | Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 144-151. | 2.8 | 51 |
| 52 | Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419. | 5.8 | 50 |
| 53 | Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4999-5003. | 3.2 | 49 |
| 54 | Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721. | 5.8 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251. | 2.2 | 47 |
| 56 | Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1071-1079. | 3.0 | 46 |
| 57 | Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. <i>Journal of Infectious Diseases</i> , 2019, 220, 635-642. | 4.0 | 43 |
| 58 | Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50. | 4.7 | 43 |
| 59 | Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 831, 248-257. | 2.3 | 42 |
| 60 | Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. <i>Lancet HIV</i> , 2021, 8, e130-e137. | 4.7 | 41 |
| 61 | Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177. | 5.8 | 40 |
| 62 | Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 271-279. | 2.1 | 40 |
| 63 | A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1227-1234. | 1.1 | 39 |
| 64 | Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. <i>Emerging Infectious Diseases</i> , 2018, 24, . | 4.3 | 38 |
| 65 | Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 478-485. | 3.0 | 37 |
| 66 | Nondaily preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 94-101. | 3.8 | 36 |
| 67 | Clinical pharmacokinetics of antiretroviral drugs in older persons. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 573-588. | 3.3 | 35 |
| 68 | Short Communication: Tenofovir Diphosphate in Dried Blood Spots As an Objective Measure of Adherence in HIV-Infected Women. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 428-432. | 1.1 | 35 |
| 69 | Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 193-198. | 2.1 | 35 |
| 70 | Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. <i>Lancet HIV</i> , 2019, 6, e498-e508. | 4.7 | 35 |
| 71 | Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e1893-e1900. | 5.8 | 35 |
| 72 | Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749. | 4.0 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2117-e2123. | 5.8 | 33 |
| 74 | Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. <i>Aids</i> , 2018, 32, 1891-1898. | 2.2 | 31 |
| 75 | A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections. <i>Drug Safety</i> , 2000, 23, 131-142. | 3.2 | 30 |
| 76 | Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7671-7679. | 3.2 | 30 |
| 77 | Pharmacologicâ€Based Methods of Adherence Assessment in <sc>HIV</sc> Prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1056-1059. | 4.7 | 29 |
| 78 | PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, . | 3.0 | 29 |
| 79 | Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2179-2188. | 3.2 | 28 |
| 80 | Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIVâ€Challenged Nonhuman Primates. <i>Advanced Therapeutics</i> , 2021, 4, 2000163. | 3.2 | 28 |
| 81 | Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. <i>Aids</i> , 2007, 21, 1849-1854. | 2.2 | 27 |
| 82 | Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment. <i>Drug Metabolism and Disposition</i> , 2011, 39, 522-527. | 3.3 | 27 |
| 83 | A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. <i>Aids</i> , 2016, 30, 743-751. | 2.2 | 27 |
| 84 | Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1988-1995. | 4.0 | 26 |
| 85 | Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 323-330. | 2.1 | 26 |
| 86 | Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 944, 18-24. | 2.3 | 25 |
| 87 | Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182. | 2.1 | 25 |
| 88 | Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LCâ€MS/MS quantification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 978-979, 163-172. | 2.3 | 24 |
| 89 | Inflammation and pharmacokinetics: potential implications for HIV-infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 641-650. | 3.3 | 24 |
| 90 | Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. <i>PLoS ONE</i> , 2019, 14, e0221281. | 2.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 295-298. | 2.1 | 23 |
| 92 | Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 463-474. | 3.3 | 23 |
| 93 | A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. <i>Pharmaceutical Research</i> , 2017, 34, 73-83. | 3.5 | 22 |
| 94 | Phase 1 Safety and Pharmacokinetics Study of MK-2048/Micriviroc (MK-4176)/MK-2048A Intravaginal Rings. <i>Clinical Infectious Diseases</i> , 2019, 68, 1136-1143. | 5.8 | 22 |
| 95 | Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. <i>Clinical Infectious Diseases</i> , 2020, 70, 687-691. | 5.8 | 22 |
| 96 | Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2470-2476. | 3.0 | 19 |
| 97 | Reduced Immune Activation During Tenofovir/Emtricitabine Therapy in HIV-Negative Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 495-501. | 2.1 | 19 |
| 98 | Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. <i>Journal of the International AIDS Society</i> , 2021, 24, e25708. | 3.0 | 19 |
| 99 | CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. <i>Aids</i> , 2004, 18, 2442-4. | 2.2 | 19 |
| 100 | Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. <i>Biomedical Chromatography</i> , 2012, 26, 12-20. | 1.7 | 18 |
| 101 | Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118. | 2.5 | 18 |
| 102 | Pharmacology supports on-demand PrEP. <i>Lancet HIV</i> , 2016, 3, e405-e406. | 4.7 | 17 |
| 103 | Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, S230-S234. | 2.1 | 17 |
| 104 | Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1228-1233. | 1.2 | 17 |
| 105 | Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821988845. | 1.5 | 17 |
| 106 | The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246. | 2.2 | 17 |
| 107 | Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 1243-1249. | 3.7 | 17 |
| 108 | Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25731. | 3.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2019, 23, 3493-3502. | 2.7 | 16 |
| 110 | Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 158-162. | 2.1 | 16 |
| 111 | Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 671-679. | 2.1 | 16 |
| 112 | In-capillary microextraction for direct mass spectrometry analysis of biological samples. <i>Talanta</i> , 2018, 189, 451-457. | 5.5 | 15 |
| 113 | Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2112-2119. | 3.0 | 15 |
| 114 | Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 166-174. | 2.1 | 15 |
| 115 | Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1149-1156. | 5.8 | 15 |
| 116 | Zidovudine and Lamivudine for HIV Infection. <i>Clinical Medicine Reviews in Therapeutics</i> , 2010, 2, a2004. | 0.2 | 15 |
| 117 | Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. <i>Aids</i> , 2022, 36, 933-940. | 2.2 | 15 |
| 118 | Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1924-1934. | 1.9 | 14 |
| 119 | Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194. | 2.2 | 14 |
| 120 | Cryopreservation of human mucosal tissues. <i>PLoS ONE</i> , 2018, 13, e0200653. | 2.5 | 14 |
| 121 | Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1395-1401. | 3.0 | 14 |
| 122 | Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. <i>Clinical Infectious Diseases</i> , 2019, 68, 1129-1135. | 5.8 | 14 |
| 123 | Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1591-1598. | 3.0 | 14 |
| 124 | Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa564. | 0.9 | 14 |
| 125 | Clinical pharmacologic considerations for HIV-1 protease inhibitors. <i>Current Infectious Disease Reports</i> , 2001, 3, 381-387. | 3.0 | 13 |
| 126 | Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 47-55. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2360-2364. | 3.0 | 13 |
| 128 | Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. <i>Pharmaceutics</i> , 2020, 12, 981. | 4.5 | 13 |
| 129 | Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program. <i>Clinical Infectious Diseases</i> , 2020, 71, e509-e512. | 5.8 | 13 |
| 130 | Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab463. | 0.9 | 13 |
| 131 | CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 280-285. | 4.7 | 12 |
| 132 | Effect of HIV-1 Infection and Sex on the Cellular Pharmacology of the Antiretroviral Drugs Zidovudine and Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3011-3019. | 3.2 | 12 |
| 133 | Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837. | 1.1 | 12 |
| 134 | Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428. | 1.1 | 12 |
| 135 | Using the adherence–efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744. | 3.0 | 12 |
| 136 | Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 251-260. | 2.1 | 12 |
| 137 | Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5387-5392. | 3.2 | 11 |
| 138 | Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1609-1618. | 3.0 | 11 |
| 139 | What Can Urine Tell Us About Medication Adherence?. <i>EClinicalMedicine</i> , 2018, 2-3, 5-6. | 7.1 | 11 |
| 140 | Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. <i>Journal of NeuroVirology</i> , 2019, 25, 324-330. | 2.1 | 11 |
| 141 | Miniature mass spectrometer–based point-of-care assay for cabotegravir and rilpivirine in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3387-3395. | 3.7 | 11 |
| 142 | Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119623. | 5.2 | 10 |
| 143 | Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. <i>PLoS ONE</i> , 2016, 11, e0165505. | 2.5 | 10 |
| 144 | Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 738-745. | 3.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 297-302. | 1.3 | 9 |
| 146 | Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2352-2359. | 3.0 | 9 |
| 147 | Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3303-3310. | 3.0 | 9 |
| 148 | Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion. <i>International Journal of Infectious Diseases</i> , 2020, 94, 41-43. | 3.3 | 9 |
| 149 | Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab200. | 0.9 | 9 |
| 150 | Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 258-265. | 3.8 | 8 |
| 151 | Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. <i>Acta Diabetologica</i> , 2016, 53, 331-333. | 2.5 | 8 |
| 152 | Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793. | 1.1 | 8 |
| 153 | Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. <i>Aids</i> , 2021, 35, 1949-1956. | 2.2 | 8 |
| 154 | Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487. | 2.2 | 8 |
| 155 | Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. <i>Aids</i> , 2022, 36, 1151-1159. | 2.2 | 8 |
| 156 | Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 123-128. | 1.1 | 7 |
| 157 | Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application. <i>Aids</i> , 2021, 35, 1823-1834. | 2.2 | 7 |
| 158 | Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 220-221. | 3.0 | 6 |
| 159 | Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 73-80. | 2.1 | 6 |
| 160 | Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680. | 3.0 | 6 |
| 161 | Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. <i>Biomedical Chromatography</i> , 2017, 31, e3820. | 1.7 | 5 |
| 162 | HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. <i>AIDS Patient Care and STDs</i> , 2020, 34, 295-302. | 2.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25849. | 3.0 | 5 |
| 164 | Reply to Stevens et al. <i>Clinical Infectious Diseases</i> , 2004, 39, 878-879. | 5.8 | 4 |
| 165 | Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. <i>Current HIV/AIDS Reports</i> , 2004, 1, 33-39. | 3.1 | 4 |
| 166 | Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 173-175. | 1.1 | 4 |
| 167 | Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa391. | 0.9 | 4 |
| 168 | Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028. | 5.8 | 4 |
| 169 | Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatch. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110105. | 1.8 | 4 |
| 170 | Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 483-488. | 2.1 | 4 |
| 171 | Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 939-943. | 1.1 | 4 |
| 172 | Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression. <i>Hepatology</i> , 2016, 64, 999-1000. | 7.3 | 3 |
| 173 | Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 3 |
| 174 | Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1200-1208. | 4.7 | 3 |
| 175 | The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP). <i>BMJ Open</i> , 2021, 11, e048993. | 1.9 | 3 |
| 176 | Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention. <i>Polymers</i> , 2022, 14, 1196. | 4.5 | 3 |
| 177 | Therapeutic drug monitoring: Pharmacologic considerations for antiretroviral drugs. <i>Current HIV/AIDS Reports</i> , 2005, 2, 61-67. | 3.1 | 2 |
| 178 | Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its isomer in human plasma. <i>Biomedical Chromatography</i> , 2014, 28, 1714-1721. | 1.7 | 2 |
| 179 | Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa577. | 0.9 | 2 |
| 180 | The use of technology-based adherence monitoring in the treatment of hepatitis C virus. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1015-1022. | 1.1 | 1 |
| 182 | Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. <i>Pharmacotherapy</i> , 2021, 41, 291-298. | 2.6 | 1 |
| 183 | A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 529-533. | 1.1 | 1 |
| 184 | A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 655-669. | 1.8 | 1 |
| 185 | Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 407-408. | 1.1 | 1 |
| 186 | Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 310-317. | 2.1 | 1 |
| 187 | Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 390-395. | 2.1 | 1 |
| 188 | Usability and effectiveness of adherence monitoring of a mobile app designed to monitor and improve adherence to event-driven and daily HIV pre-exposure prophylaxis among men who have sex with men in Taiwan. <i>Digital Health</i> , 2022, 8, 205520762211027. | 1.8 | 1 |
| 189 | Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens. <i>Pharmacotherapy</i> , 0, , . | 2.6 | 1 |
| 190 | Stability of zidovudine with oxytocin in a simulated Y-site injection. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 394-396. | 1.0 | 0 |
| 191 | Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV. <i>Frontiers in Pharmacology</i> , 2020, 11, 1288. | 3.5 | 0 |
| 192 | OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , . | 3.0 | 0 |